La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Valneva Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Valneva ha un patrimonio netto totale di €166.3M e un debito totale di €180.4M, che porta il suo rapporto debito/patrimonio netto a 108.5%. Le sue attività totali e le sue passività totali sono rispettivamente €466.6M e €300.3M.

Informazioni chiave

108.5%

Rapporto debito/patrimonio netto

€180.42m

Debito

Indice di copertura degli interessi	n/a
Contanti	€131.41m
Patrimonio netto	€166.28m
Totale passività	€300.29m
Totale attività	€466.57m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 17

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 10

Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Apr 05

Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Mar 27

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

Mar 15

News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Jan 06

Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Dec 13

Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Aug 10

Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry

May 12

Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Jan 30

Is Valneva (EPA:VLA) Using Debt Sensibly?

Sep 18

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €269.2M ) di VLA superano le sue passività a breve termine ( €102.5M ).

Passività a lungo termine: Le attività a breve termine di VLA ( €269.2M ) superano le sue passività a lungo termine ( €197.8M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 29.5% ) di VLA è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di VLA è aumentato da 11.2% a 108.5% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: VLA ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: Dati insufficienti per determinare se VLA ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.

Valneva Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Is Valneva (EPA:VLA) Using Debt Sensibly?

Recent updates

Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Consensus EPS estimates fall from profit to €0.05 loss

Second quarter 2024 earnings released: €0.19 loss per share (vs €0.12 loss in 2Q 2023)

No longer forecast to breakeven

Consensus EPS estimates fall by 75%

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings released: EPS: €0.42 (vs €0.13 loss in 1Q 2023)

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Full year 2023 earnings released: €0.73 loss per share (vs €1.24 loss in FY 2022)

New minor risk - Profitability

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Consensus EPS estimates fall by 19%

Forecast to breakeven in 2024

Valneva Se Announces Earnings Guidance for 2024

Consensus EPS estimates upgraded to €0.05 loss

Consensus EPS estimates fall by 103%

Price target decreased by 8.6% to €9.17

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

No longer forecast to breakeven

Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

New minor risk - Financial position

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Consensus EPS estimates upgraded to €0.12 loss

Valneva Se Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

Valneva SE announced a financing transaction

Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Price target increased by 8.3% to €9.73

Forecast breakeven date moved forward to 2023

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry

Valneva SE Provides Financial Guidance of 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Consensus EPS estimates fall by 91%, revenue upgraded

Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Consensus forecasts updated

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Reiterates Earnings Guidance for the Fiscal 2022

Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences

Valneva SE announced a financing transaction